Novo Nordisk invests $2.3 billion in France for obesity drug production

Novo Nordisk announced a $2.3 billion investment to boost production capacity for obesity and diabetes drugs at its site in Chartres, France, including Ozempic and Wegovy.

“Novo Nordisk on Thursday announced a $2.3 billion investment to boost production of its wildly popular weight-loss and diabetes drugs at a site in Chartres, France as it races to meet soaring demand.”uk.investing.com

• 1 source
• uk.investing.comNovo Nordisk invests $2.3 billion in France to boost obesity drug production By ReutersNov 23, 2023

Summarized from public sources; check the original articles before acting on it.